Dr. Dennehy has proven leadership, technical, and interpersonal skills which have been used to deliver high profile projects within a global pharma company. Robert’s core expertise is in API solid state and crystallization but spans chemistry and formulation. This breadth has been critical in solving problems in crystallisation, solid state selection, polymorph control, micronisation, API filtration and in the formulation of OSDs and inhaled products.
Robert played a critical role in the development of more than 10 late phase and marketed NCEs including QbD and risk assessment. Responsible for the crystallization and solid state development of all GSK small molecule assets, numbering over 30.
Robert has a PhD in Chemistry from Southampton University, UK, and a B.Sc. in Chemistry from Queen Mary College, University of London.
He resides in London, UK and has been based across 7 sites in the UK, Europe and the US.